During a conference in CAESAREA, Israel on December 10, 2025, abstracts of 3 studies were presented involving a total of 263 patients. These studies contribute to the increasing evidence base supporting the wider use of ProSense®. IceCure Medical Ltd. (NASDAQ: ICCM) shared this information, highlighting the positive results across diverse patient populations.